Oral liquid drugs play a vital role for patients who have difficulty swallowing tablets and for those requiring personalised dosing.

Eisai secured worldwide rights for the development and marketing of the antibody for Alzheimer’s disease treatment in an agreement with BioArctic in December 2007. Credit: David Gyung/Shutterstock.com ...

Genmab has signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn.

More than two-thirds – 67% - of first responders organisations have deployed new cybersecurity protections in the last 12 ...

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb).

Amgen has revealed a significant investment plan, earmarking $650m to enhance its manufacturing operations in the US.

The 100% rate on imported, branded pharma products will not apply to drugmakers constructing manufacturing facilities in the ...

Lilly has received approval from the US Food and Drug Administration (FDA) for Inluriyo (imlunestrant) to treat advanced ...

Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.

Bucking the trend of IL-12 therapy programme failures, Imunon’s IMNN-001 was bolstered by positive translational data in ...

Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under ...